Sonnet BioTherapeutics Holdings, Inc. (SONN)
Dec 2, 2025 - SONN was delisted (reason: merged into PURR)
1.260
-1.840 (-59.35%)
Inactive · Last trade price on Dec 2, 2025

SONN Income Statement

Millions USD. Fiscal year is Oct - Sep.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20
-0.020.150.350.48-
Revenue Growth (YoY)
--87.40%-57.76%-27.64%--
Gross Profit
-0.020.150.350.48-
Selling, General & Admin
7.666.137.138.588.947.53
Research & Development
7.45.7411.8121.4416.6316.7
Total Operating Expenses
15.0611.8718.9430.0225.5724.24
Operating Income
-15.06-11.85-18.79-29.67-25.09-24.24
Interest Income
----00.02
Other Non-Operating Income (Expense)
-0.064.41-0.04-0.050.1-0.05
Total Non-Operating Income (Expense)
-0.064.41-0.04-0.050.1-0.03
Pretax Income
-15.12-7.44-18.83-29.72-24.98-24.27
Net Income
-15.12-7.44-18.83-29.72-24.98-65.6
Net Income Attributable to Preferred Dividends
------41.34
Net Income to Common
-15.12-7.44-18.83-29.72-24.98-65.6
Shares Outstanding (Basic)
310000
Shares Outstanding (Diluted)
310000
Shares Change (YoY)
457.92%404.96%425.71%147.76%160.57%3409.64%
EPS (Basic)
-7.11-11.35-145.13-1204.16-2508.00-17149.44
EPS (Diluted)
-7.08-11.35-145.13-1204.16-2508.00-17149.44
Free Cash Flow
-0-21.34-27.77-22.56-15.69
Free Cash Flow Per Share
---164.47-1125.22-2264.11-4104.09
Gross Margin
-100.00%100.00%100.00%100.00%-
Operating Margin
--63617.91%-12714.47%-8478.34%-5187.36%-
Profit Margin
--39929.30%-12741.58%-8493.34%-5165.97%-
FCF Margin
-0.00%-14439.19%-7936.59%-4663.91%-
EBITDA
-15.06-11.85-18.72-29.58-24.99-24.18
EBITDA Margin
--63617.91%-12663.22%-8451.69%-5167.69%-
EBIT
-15.06-11.85-18.79-29.67-25.09-24.24
EBIT Margin
--63617.91%-12714.47%-8478.34%-5187.36%-
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q